[Video] Cue Biopharma Q&A Session With Dr. D.J. Verret
In this 1.5 hour webinar, Dr. D.J. Verret shares his unique clinical perspective on Cue Biopharma’s (CUE) approach and latest data
In this 1.5 hour webinar, Dr. D.J. Verret shares his unique clinical perspective on Cue Biopharma’s (CUE) approach and latest data
Here’s a full rundown on the important takeaways from CUE’s conference call and my thoughts on the recent trading activity…
Like expectant parents, everyone’s wondering what will be revealed on today’s update call. Here are my reasonable expectations…
Five key takeaways from Cue Biopharma’s Q1 2019 report, including the list of catalysts management believes will result in 2019 being a “transformational” year…
Here are three reasons why today’s FDA approval to enter the clinic with CUE-101 for HPV-associated cancers is significant, including two not so obvious reasons. Plus, a list of catalysts for 2019…